已确认可信度 87%Bayer's[1] release is stamped "24 October 2025 | 19:25 PM Europe/Amsterdam" and opens "Berlin, October 24, 2025 - Bayer announced today that the U.S. Food and Drug Administration (FDA[2]) has approved elinzanetant".
The FDA approves Bayer's Lynkuet (elinzanetant), the first drug to block both the NK1 and NK3 receptors, as a hormone-free treatment for moderate to severe hot flashes of menopause.
已确认可信度 87%The release dated 27 October 2025 says HUMAIN and Qualcomm[1][2][3][4] 'today announced' the collaboration 'ahead of the 9th edition of the Future Investment Initiative (FII) conference'.
Saudi AI company HUMAIN became the first customer for Qualcomm's data-centre chips, targeting 200 megawatts of AI200 and AI250 racks from 2026 to sell AI inference services in the Kingdom and worldwide.
已确认可信度 84%CNBC[4] reports 'Qualcomm[1][2][3] announced Monday' (Mon, Oct 27 2025, published 10:00 AM EDT) that it will release the AI200 and AI250; Qualcomm's release carries the same announcement.
Qualcomm entered the data-center AI market with the AI200 and AI250 accelerator cards and liquid-cooled racks, with 768 GB of memory per card, due in 2026 and 2027; its stock jumped 11% that day.